sVEGFR2抗体

sVEGFR2抗体经ICC, IHC严格验证,品质保证.适用于多种种属反应性,被多篇文献引用并有用户反馈信息.确保特异性!产品具有以下特点:

1、全：网络全世界的上等产品，基本上各种抗体产品在该公司均能找到

2、新：产品及网站更新非常快，基本上每周均有新产品出现

3、优：产品质量好，投诉比较少

4、强：强大的技术支持队伍和力量，网站上有齐全的技术资料以及客户评论，并提供实时在线技术咨询，使您使用产品时没有任何后顾之忧。

产品编号xy-2089R

英文名称sVEGFR2

中文名称可溶性血管内皮生长因子受体2抗体

别    名sFLK-1; truncated soluble vascular endothelial growth factor receptor 2.  

说 明 书100ul  200ul

研究领域肿瘤  细胞生物  神经生物学  信号转导  生长因子和**  激酶和磷酸酶  血管内皮细胞  

抗体来源Rabbit

克隆类型Polyclonal

sVEGFR2抗体交叉反应 Human,

产品应用WB=1:500-2000 ELISA=1:500-1000 Flow-Cyt=1μg /test （石蜡切片需做抗原修复）

not yet tested in other applications.

optimal dilutions/concentrations should be determined by the end user.

分 子 量75kDa

性    状Lyophilized or Liquid

浓    度1mg/1ml

免 疫 原KLH conjugated synthetic peptide derived from human sVEGFR2

亚    型IgG

纯化方法affinity purified by Protein A

储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.

保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.

PubMedPubMed

产品介绍background:

Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. This gene encodes one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas. [provided by RefSeq, May 2009].

Function:

Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFA, VEGFC and VEGFD. Plays an essential role in the regulation of angiogenesis, vascular development, vascular permeability, and embryonic hematopoiesis. Promotes proliferation, survival, migration and differentiation of endothelial cells. Promotes reorganization of the actin cytoskeleton. Isoforms lacking a transmembrane domain, such as isoform 2 and isoform 3, may function as decoy receptors for VEGFA, VEGFC and/or VEGFD. Isoform 2 plays an important role as negative regulator of VEGFA-and VEGFC-mediated lymphangiogenesis by limiting the amount of free VEGFA and/or VEGFC and preventing their binding to FLT4. Modulates FLT1 and FLT4 signaling by forming heterodimers. Binding of vascular growth factors to isoform 1 leads to the activation of several signaling cascades. Activation of PLCG1 leads to the production of the cellular signaling molecules diacylglycerol and inositol 1,4,5-trisphosphate and the activation of protein kinase C. Mediates activation of MAPK1/ERK2, MAPK3/ERK1 and the MAP kinase signaling pathway, as well as of the AKT1 signaling pathway. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, reorganization of the actin cytoskeleton and activation of PTK2/FAK1. Required for VEGFA-mediated induction of NOS2 and NOS3, leading to the production of the signaling molecule nitric oxide (NO) by endothelial cells. Phosphorylates PLCG1. Promotes phosphorylation of FYN, NCK1, NOS3, PIK3R1, PTK2/FAK1 and SRC.

Subunit:

Interacts with MYOF (By similarity). Interacts with VEGFA, VEGFC and VEGFD. Monomer in the absence of bound VEGFA, VEGFC or VEGFD. Homodimer in the presence of bound dimeric VEGFA, VEGFC or VEGFD. Can also form heterodimers with FLT1 and FLT4. Interacts (tyrosine phosphorylated) with FYN, NCK1, PLCG1 and SHB. Interacts with HIV-1 Tat. Interacts with CBL. Interacts with SH2D2A/TSAD and GRB2.

Subcellular Location:

Isoform 1: Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Cytoplasmic vesicle. Early endosome. Note=Detected on caveolae-enriched lipid rafts at the cell surface. Is recycled from the plasma membrane to endosomes and back again. Phosphorylation triggered by VEGFA binding promotes internalization and subsequent degradation. VEGFA binding triggers internalization and translocation to the nucleus.

Isoform 2: Secreted (Probable).

Isoform 3: Secreted.

Tissue Specificity:

Detected in cornea (at protein level). Widely expressed.

Post-translational modifications:

N-glycosylated.

Ubiquitinated. Tyrosine phosphorylation of the receptor promotes its poly-ubiquitination, leading to its degradation via the proteasome or lysosomal proteases.

Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation at Tyr-951 is important for interaction with SH2D2A/TSAD and VEGFA-mediated reorganization of the actin cytoskeleton. Phosphorylation at Tyr-1175 is important for interaction with PLCG1 and SHB. Phosphorylation at Tyr-1214 is important for interaction with NCK1 and FYN. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.

DISEASE:

Defects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.

Note=Plays a major role in tumor angiogenesis. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.

Similarity:

Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.

Contains 7 Ig-like C2-type (immunoglobulin-like) domains.

Contains 1 protein kinase domain.

SWISS:

P35968

Gene ID:

3791

抗体选择指南

sVEGFR2抗体检测任何目的靶蛋白都有不止一种抗体可供选择，为缩小抗体的选择范围选中合适的抗体，需要考虑如下几种因素：

（1） 分析或应用的类型

（2）样本蛋白的结构性质

（3）样本的种属

（4）抗体宿主的种类

（5）抗体的标记和检测

1 分析试验的应用类型一般抗体说明书都列出该抗体经试验验证过适用于何种分析类型，如：

可以应用于WB IHC ICC ELASA 分析等，如果抗体说明书没有提及的应用类型，并不意味着该抗体不适用于此种分析应用类型，而仅是说明尚未经过此种分析试验验证，如果抗体不适用某些分析试验，则会在抗体说明书上标注出来不适于某分析试验。

2 样本蛋白的结构性质了解样本蛋白的结构性质有助于选择*合适的抗体，至少需要考虑两方面因素

(1)..待测样本蛋白的结构域：sVEGFR2抗体是由各种不同**原**宿主而制备得来，其中的**原包括：全长蛋白、蛋白片断、多肽、全有机体（如：**）或细胞，抗体说明书一般都有**原的描述，如果打算检测的是蛋白片断或一种特殊的同型物或蛋白全长的某一区域，则必须选择用含此片段域的**原制备出的抗体。如果打算用FACS 流式检测活细胞的表面蛋白，则需要选择含该表面蛋白的胞外域来**制备的抗体。

(2)样本的提取或处理过程：某些抗体要求样本经过某些特殊处理，例如：许多抗体只识别还原和变性的、表位已暴露不受二级四级结构阻碍的蛋白样本，另一方面，某些抗体仅识别天然折叠状态的蛋白。

当选择**组化的抗体时，应注意某些抗体只识别未固定的冷冻的组织，而另一些抗体则适用于无需抗原修复解交联步聚的甲醛固定石蜡包埋的组织，这些都会在抗体说明书上应用部分标示出来 3 样本的物种 应选择物种相同或有交叉反应的抗体，抗体可能与不同物种的同种靶蛋白有交叉反应，因其氨基酸序列同源性较高。

如果样本的种类未列入抗体说明书上的交叉反应种属表中，并不意味着该抗体不适用于检测该物种的蛋白，而只是表示该物种尚未用此抗体检测验证过，应通过序列比对的方法来预测交叉反应，sVEGFR2抗体可应用Expasy 和 NCBI BLAST 来进行不同物种蛋白同源性比对。

4 一抗宿主物种的选择一般说来，在使用偶联二抗结合无偶联物的一抗时，一抗宿主动物的物种选择较为重要，对于**组化而言，尽可能选择与样本不同种系物种的一抗，从而避免二抗与样本内源性**球蛋白产生交叉反应，

例如：检测小鼠样本蛋白，则不应选择小鼠或大鼠源的一抗，*好选兔源的一抗，则二抗则可选择偶联了检测分子（酶、荧光素、生物素等）的抗兔IgG。如果选择有偶联物的一抗则不适用上述情况，除**组化外的其它对不含内源性**球蛋白样本的检测方法，则抗体宿主物种的影响不大，如对不含IgG 的细胞裂解物样本的western blotting检测。

尽管如此，sVEGFR2抗体含有血清的组织裂解物和组织培养上清中含有**球蛋白，还原变性样本中含IgG，在western blot 检测中则结合出现IgG 分子50 and 25 kDa 的重链和轻链条带。

5 二抗的选择 二抗应选用与使用的一抗相同的物种来源，例如：如果你的一抗是小鼠的单克隆抗体，二抗则选抗小鼠的二抗anti-mouse secondary。建议检查二抗说明书确保该抗体适用于你的检测应用， 二抗一般连接荧光素FITC 或发光团。

6 双重染色抗体的选择用未偶联一抗进行细胞培养物或组织切片的双重**染色要求一抗来源于不同物种并且二抗分别识别其中之一，二抗说明书应描述其与其它物种来源的**球蛋有否有交叉吸附。

合格 RNF211 环指蛋白211抗体
合格 合格 caspase-9 p10 半胱胺酸蛋白酶蛋白9-p10抗体 
合格 hnRNP M 异质性核糖核蛋白M抗体
合格 OSTM1 骨硬化病相关跨膜蛋白1抗体
合格 Reg3a precursor 胰岛β细胞生长因子抗体
合格 合格 MSX1 MSH同源蛋白1样蛋白抗体
合格 MtTF1/TFAM 线粒体转录因子1抗体
合格 Calcium Sensing Receptor 钙敏感受体1抗体
合格 合格 TPP1 细胞生长抑制基因1蛋白抗体
合格 合格 Vimentin 波形蛋白抗体
合格 合格 TRPV5 辣椒素受体5抗体
合格 合格 Nucleolin/C23 核仁蛋白C23抗体
合格 EP4 前列腺素E受体蛋白4抗体
合格 CLEC 4E C型凝集素4家族E抗体
合格 合格 GABR B3 G氨基丁酸受体3抗体
合格 TRAF4 肿瘤坏死因子受体相关蛋白4抗体
合格 合格 3-Nitrotyrosine 硝基酪氨酸抗体
合格 Desmuslin 中间丝蛋白β-synemin抗体
合格 non-muscle Myosin IIA 非平滑肌肌球蛋白2A抗体
合格 Phospho-NMDAR2B (Tyr1474) 磷酸化谷氨酸受体2B抗体
合格 FSIP1 纤维性鞘结合蛋白1抗体
合格 Arginase 1 精氨酸酶1抗体
合格 DOK5 胞浆接头蛋白Dok5抗体
合格 Etv5 转录因子Ets差异基因5抗体
合格 phospho-PKC Epsilon(Ser729) 磷酸化蛋白激酶C/p-PKC ε抗体
合格 LGR6 G蛋白偶联受体6抗体
合格 SLC20A2 溶质载体蛋白家族20成员2抗体

产品留言

标题

联系人

联系电话

内容

验证码

点击换一张

注：1.可以使用快捷键Alt+S或Ctrl+Enter发送信息!
2.如有必要,请您留下您的详细联系方式!